135 related articles for article (PubMed ID: 36788073)
1. Identifying SOX17 as a Sensitive and Specific Marker for Ovarian and Endometrial Carcinomas.
Shaker N; Chen W; Sinclair W; Parwani AV; Li Z
Mod Pathol; 2023 Jan; 36(1):100038. PubMed ID: 36788073
[TBL] [Abstract][Full Text] [Related]
2. SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas.
Zhang X; Yao J; Niu N; Li X; Liu Y; Huo L; Euscher ED; Wang H; Bell D; Sood AK; Wang G; Lawson BC; Ramalingam P; Malpica A; Sahin AA; Ding Q; Liu J
Mod Pathol; 2023 Feb; 36(2):100001. PubMed ID: 36853778
[TBL] [Abstract][Full Text] [Related]
3. SOX17 is a highly sensitive and specific marker for metastatic ovarian and endometrial carcinomas in cytology cell block specimens.
Satturwar S; Shaker N; Sinclair W; Shen R; Parwani AV; Ding Q; Li Z
Cancer Cytopathol; 2023 Jul; 131(7):465-470. PubMed ID: 37195085
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive analysis of PAX8 expression in human epithelial tumors.
Laury AR; Perets R; Piao H; Krane JF; Barletta JA; French C; Chirieac LR; Lis R; Loda M; Hornick JL; Drapkin R; Hirsch MS
Am J Surg Pathol; 2011 Jun; 35(6):816-26. PubMed ID: 21552115
[TBL] [Abstract][Full Text] [Related]
5. PAX8 mouse monoclonal antibody [BC12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with b cells and tumors of pancreatic origin.
Tacha D; Qi W; Zhou D; Bremer R; Cheng L
Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):59-63. PubMed ID: 22595948
[TBL] [Abstract][Full Text] [Related]
6. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.
Nonaka D; Chiriboga L; Soslow RA
Am J Surg Pathol; 2008 Oct; 32(10):1566-71. PubMed ID: 18724243
[TBL] [Abstract][Full Text] [Related]
7. PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors.
Wang M; Ma H; Pan Y; Xiao W; Li J; Yu J; He J
Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):280-7. PubMed ID: 24992169
[TBL] [Abstract][Full Text] [Related]
8. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study.
Tacha D; Zhou D; Cheng L
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):293-9. PubMed ID: 21285870
[TBL] [Abstract][Full Text] [Related]
9. PAX8 expression in uterine adenocarcinomas and mesonephric proliferations.
Yemelyanova A; Gown AM; Wu LS; Holmes BJ; Ronnett BM; Vang R
Int J Gynecol Pathol; 2014 Sep; 33(5):492-9. PubMed ID: 25083965
[TBL] [Abstract][Full Text] [Related]
10. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
11. Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium.
Iwamoto M; Nakatani Y; Fugo K; Kishimoto T; Kiyokawa T
Hum Pathol; 2015 Jul; 46(7):957-62. PubMed ID: 25971546
[TBL] [Abstract][Full Text] [Related]
12. The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17.
Chaves-Moreira D; Mitchell MA; Arruza C; Rawat P; Sidoli S; Nameki R; Reddy J; Corona RI; Afeyan LK; Klein IA; Ma S; Winterhoff B; Konecny GE; Garcia BA; Brady DC; Lawrenson K; Morin PJ; Drapkin R
Sci Signal; 2022 Apr; 15(728):eabm2496. PubMed ID: 35380877
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of paired box genes 8 and 2 expression in epithelium tissues and the related tumors].
Song Y; Huang X; Shen GH; Liu XY; Zhang X
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):424-428. PubMed ID: 28635231
[No Abstract] [Full Text] [Related]
14. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
15. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
Ates Ozdemir D; Usubutun A
Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
[TBL] [Abstract][Full Text] [Related]
16. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin.
Woodard AH; Yu J; Dabbs DJ; Beriwal S; Florea AV; Elishaev E; Davison JM; Krasinskas AM; Bhargava R
Am J Clin Pathol; 2011 Sep; 136(3):428-35. PubMed ID: 21846919
[TBL] [Abstract][Full Text] [Related]
17. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms.
Kubba LA; McCluggage WG; Liu J; Malpica A; Euscher ED; Silva EG; Deavers MT
Mod Pathol; 2008 Apr; 21(4):485-90. PubMed ID: 18246044
[TBL] [Abstract][Full Text] [Related]
18. PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy.
Wang Y; Wang Y; Li J; Yuan Z; Yuan B; Zhang T; Cragun JM; Kong B; Zheng W
J Hematol Oncol; 2013 Aug; 6():60. PubMed ID: 23958394
[TBL] [Abstract][Full Text] [Related]
19. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
McKnight R; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of preferentially expressed antigen in melanoma (PRAME) in testicular germ cell tumors - A comparative study with SOX17.
Zhou Y; Rothrock A; Murugan P; Li F; Bu L
Exp Mol Pathol; 2022 Jun; 126():104761. PubMed ID: 35390309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
